The award will help Akonni accelerate the advancement of its proprietary technologies to address the critically unmet need for simple, effective, and affordable tools to diagnose lower respiratory diseases in children.
Conventional diagnostic techniques require long turnaround times, lack the required sensitivity, and have limited ability to test for a variety of different respiratory pathogens simultaneously. Recently developed multiplexed molecular diagnostic respiratory panels offer the potential to address these issues.
Akonni Biosystems has been issued 21 US and 36 international patents primarily covering sample preparation, microfluidic devices, bioinstrumentation, and integrated systems.
Commercial products in the company's near-term pipeline include rapid sample preparation technologies for nucleic acid extraction, and multiplex panel assays for detecting clinically relevant genotypes for pharmacogenomics, human chronic diseases, and genotypes for infectious diseases.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary